These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7867436)

  • 1. [Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections].
    Li JT; Hou J; Kao L
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):440-3. PubMed ID: 7867436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
    Kardos P; Wiese K
    MMW Fortschr Med; 2000 Feb; 142(5):41. PubMed ID: 10715939
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 5. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients.
    Ito K; Ito M
    J Chemother; 1995 Nov; 7 Suppl 4():124-6. PubMed ID: 8904131
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections.
    Muranaka H; Yokoyama M
    J Chemother; 1995 Nov; 7 Suppl 4():127-30. PubMed ID: 8904132
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
    Cox CE; Graveline JF; Luongo JM
    Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
    Terui T; Tagami H
    J Chemother; 1995 Nov; 7 Suppl 4():119-21. PubMed ID: 8904129
    [No Abstract]   [Full Text] [Related]  

  • 9. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H; Kitahara T; Yoshinaga M; Miyata K
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
    Safran C
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
    Stevens DL; Pien F; Drehobl M
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil].
    Vyhnánek F; Lochmann O
    Epidemiol Mikrobiol Imunol; 1996 May; 45(2):68-70. PubMed ID: 8756403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract]   [Full Text] [Related]  

  • 17. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical studies of cefpodoxime proxetil in pediatric field].
    Kimura S; Yokoyama M; Kudo M; Aoyama R; Okamoto T; Tsushima N; Onodera N; Ikeda Y
    Jpn J Antibiot; 1989 Jul; 42(7):1477-87. PubMed ID: 2810724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
    Zuck P; Rio Y; Ichou F
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():71-7. PubMed ID: 2292534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.